BRPI0403291A - Métodos para avaliação e tratamento de câncer - Google Patents
Métodos para avaliação e tratamento de câncerInfo
- Publication number
- BRPI0403291A BRPI0403291A BR0403291-8A BRPI0403291A BRPI0403291A BR PI0403291 A BRPI0403291 A BR PI0403291A BR PI0403291 A BRPI0403291 A BR PI0403291A BR PI0403291 A BRPI0403291 A BR PI0403291A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- patient
- treatment methods
- fti
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61144603A | 2003-07-01 | 2003-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0403291A true BRPI0403291A (pt) | 2005-07-12 |
Family
ID=33541317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0403291-8A BRPI0403291A (pt) | 2003-07-01 | 2004-07-01 | Métodos para avaliação e tratamento de câncer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1502962A3 (https=) |
| JP (1) | JP2005034151A (https=) |
| KR (1) | KR20050004076A (https=) |
| CN (1) | CN1626679A (https=) |
| AR (1) | AR044984A1 (https=) |
| AU (1) | AU2004202980B2 (https=) |
| BR (1) | BRPI0403291A (https=) |
| CA (1) | CA2472846A1 (https=) |
| MX (1) | MXPA04006494A (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050003422A1 (en) * | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| JP2005333987A (ja) * | 2004-05-06 | 2005-12-08 | Veridex Llc | 悪性血液疾患の予後 |
| US20090186024A1 (en) * | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
| WO2008156613A1 (en) * | 2007-06-12 | 2008-12-24 | Schering Corporation | Histone h2ax (hh2ax) biomarker for fti sensitivity |
| TW201326481A (zh) * | 2011-08-30 | 2013-07-01 | Nat Defense Medical Ct | 預測易罹患卵巢贅瘤或卵巢癌預後之生物標記 |
| CN109628591B (zh) * | 2018-12-04 | 2022-04-15 | 南方医科大学南方医院 | 用于肺腺癌预后预测的标志物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005522990A (ja) * | 2001-10-30 | 2005-08-04 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | 白血病の評価及び処理方法 |
-
2004
- 2004-06-30 AU AU2004202980A patent/AU2004202980B2/en not_active Ceased
- 2004-06-30 EP EP04253943A patent/EP1502962A3/en not_active Withdrawn
- 2004-07-01 AR ARP040102323A patent/AR044984A1/es unknown
- 2004-07-01 MX MXPA04006494A patent/MXPA04006494A/es not_active Application Discontinuation
- 2004-07-01 JP JP2004195973A patent/JP2005034151A/ja active Pending
- 2004-07-01 BR BR0403291-8A patent/BRPI0403291A/pt not_active IP Right Cessation
- 2004-07-01 KR KR1020040051209A patent/KR20050004076A/ko not_active Ceased
- 2004-07-01 CN CNA2004100640771A patent/CN1626679A/zh active Pending
- 2004-07-02 CA CA002472846A patent/CA2472846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2472846A1 (en) | 2005-01-01 |
| JP2005034151A (ja) | 2005-02-10 |
| EP1502962A2 (en) | 2005-02-02 |
| AR044984A1 (es) | 2005-10-12 |
| MXPA04006494A (es) | 2005-04-19 |
| KR20050004076A (ko) | 2005-01-12 |
| AU2004202980A1 (en) | 2005-01-20 |
| CN1626679A (zh) | 2005-06-15 |
| AU2004202980B2 (en) | 2009-05-07 |
| EP1502962A3 (en) | 2006-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor α (ER) promoter upon reactivation in ER-negative human breast cancer cells | |
| BRPI0502433A (pt) | métodos para avaliação e tratamento de cáncer | |
| Caffo et al. | Heavy metals and epigenetic alterations in brain tumors | |
| WO2004053066A3 (en) | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy | |
| ATE541053T1 (de) | Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs | |
| BRPI0503418A (pt) | prognóstico para malignidade hematológica | |
| BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
| BR0007532A (pt) | Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente | |
| WO2006133420A3 (en) | Treatment of patients with cancer therapy | |
| EP1466174A4 (en) | MUTATIONS IN BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 | |
| DE60222590D1 (de) | Methoden zur feststellung von akute myeloischen leukämie | |
| BR0214840A (pt) | Genes | |
| WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
| BR0210720A (pt) | Composto e uso do mesmo | |
| BRPI0408466A (pt) | composições farmacêuticas de inibidores de cetp e uso dos referidos inibidores | |
| BRPI0403291A (pt) | Métodos para avaliação e tratamento de câncer | |
| DE602006015966D1 (de) | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie | |
| BRPI0408268A (pt) | moléculas e métodos de prevenção ou inibição da atividade da malária in vivo e de tratamento de pessoas | |
| SE0102147D0 (sv) | New methods | |
| Feng et al. | N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: sequence preference and the effect of C5 cytosine methylation | |
| WO2005047536A3 (en) | Detection of genomic amplification and deletion in cancer | |
| WO2003011215A3 (en) | Method and system to determine revised dosage | |
| Dudzik et al. | The epigenetic modifier 5-Aza-2-deoxycytidine triggers the expression of CD146 gene in prostate cancer cells | |
| EP1451552A4 (en) | FOR DETECTING DISORDERS OF BREAST SUITABLE REAGENTS AND METHODS | |
| Pollack et al. | Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |